Phase 3 Results for Olokizumab in RA Patients

No new safety signals identified during the study. Additionally, there were no noticeable efficacy or safety differences between the olokizumab doses.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

1. Nasonov E, Fatenejad S, Korneva E, et al. Safety and efficacy of olokizumab in a phase 3 trial of patients with moderately to severely active rheumatoid arthritis inadequately controlled by methotrexate—CREDO1 study [abstract L12]. Arthritis Rheumatol. 2019 Oct; 71(suppl 10).